by Gizelle Baker, Patrick Picavet, Maurice Smith, Patrick Vanscheeuwijck and Manuel C. Peitsch2
Philip Morris International R&D
A PDF VERSION OF THE FULL SUMMARY RESPONSE IS AVAILABLE HERE.
The Department of Medicine, University of California, and San Francisco, California, USA has recently published a letter in Tobacco Control claiming that “The preclinical and clinical data PMI submitted to FDA indicate that IQOS exposure may be associated with unexpected liver toxicity. We reviewed preclinical studies conducted by PMI scientists and clinical studies of 5 and 90 days of exposure to IQOS and IQOS menthol included in PMI’s Modified Risk Tobacco Product application submitted to the US FDA.”
In summary, we have assessed these claims based on a careful review of our scientific data submitted to FDA. The scientific data is in the FDA submission and requires knowledge of the design and conduct of toxicology and clinical studies, together with a careful and detailed review of the resulting data to reach accurate, science-based conclusions. Such an analysis was not performed by the authors of the letter and therefore the conclusions they have drawn are incorrect and misleading.
We have prepared a point-by-point assessment of the claims made by the authors and this detailed analysis can be found here.
In conclusion, based on an analysis of our toxicological studies and clinical studies performed according to international standards of good practice, there is no evidence that IQOS use leads to hepatotoxicity.
 Department of Medicine, University of California, San Francisco, San Francisco, California, USA
 Philip Morris Products S.A., PMI Research and Development, Quai Jeanrenaud 5, 2000 Neuchâtel, Switzerland. Authors are listed in alphabetical order.